XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 180,347 $ 356,082 [1]
Short-term marketable securities 419,264 251,011 [1]
Receivable from licensing and collaboration agreements 7,710  
Receivable from a related party 462  
Prepaid expenses and other current assets 31,927 35,731 [1]
Total current assets 639,710 642,824 [1]
Investment in equity securities 17,707  
Property and equipment, net 27,741 20,325 [1]
Operating lease right-of-use assets 17,108 16,508 [1]
Intangible assets, net 46,204  
Other assets 33,054 23,931 [1]
Total assets 781,524 703,588 [1]
Current liabilities:    
Accounts payable 12,035 8,945 [1]
Accrued compensation and benefits 21,560 29,682 [1]
Accrued research and development liabilities 37,645 27,290 [1]
Accrued professional services 4,976 5,579 [1]
LEO call option liability [1]   5,550
Operating lease liabilities, current portion 4,999 3,795 [1]
Term loans, current portion [1]   1,458
Other accrued liabilities 14,608 13,349 [1]
Total current liabilities 95,823 95,648 [1]
Term loans, net of current portion 103,138 92,421 [1]
Operating lease liabilities, net of current portion 18,683 14,677 [1]
Other long-term liabilities 27,578 9,520 [1],[2]
Total liabilities 1,517,398 595,702 [1]
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests 2,967 1,630 [1]
Stockholders’ equity (deficit):    
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 153,279,652 shares issued and 147,087,891 shares outstanding as of September 30, 2021, 125,264,070 shares issued and 122,849,389 shares outstanding as of December 31, 2020 153 125 [1]
Treasury stock, at cost; 6,191,761 shares as of September 30, 2021, 2,414,681 shares as of December 31, 2020 (275,000) (75,000) [1]
Additional paid-in capital 821,220 1,021,344 [1]
Accumulated other comprehensive income 19 192 [1]
Accumulated deficit (1,289,789) (888,755) [1]
Total BridgeBio stockholders’ equity (deficit) (743,397) 57,906 [1]
Noncontrolling interests 4,556 48,350 [1]
Total stockholders’ equity (deficit) (738,841) 106,256 [1],[3]
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ equity (deficit) 781,524 703,588 [1]
2029 Notes    
Current liabilities:    
Notes, net 732,659  
Term loans, net of current portion 732,659  
2027 Notes    
Current liabilities:    
Notes, net 539,517 383,436 [1]
Term loans, net of current portion $ 539,517 $ 383,436
[1] The condensed consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date.
[2] Related deferred tax liability was recorded as part of “Other long-term liabilities.”
[3] The consolidated balances as of December 31, 2020 and 2019 are derived from the audited consolidated financial statements as of those dates.